Compare BioNano Genomics Inc (BNGO) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Payoneer Global Inc — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Payoneer Global Inc trades at $7.1 (market cap $2.40B). The key difference: Payoneer Global Inc is far larger — about 175.7× BioNano Genomics Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | PAYO | |
|---|---|---|
Market Cap | $13.66M | $2.40B |
Sector | Health | Technology |
52-Week High | $4.92 | $7.17 |
52-Week Low | $1.06 | $4.27 |
Enterprise Value | $16.26M | $2.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
PAYO trades at $7.095, up 0.07% today, near its 52-week high of $7.67. The stock shows a bullish technical signal with moving averages supporting upside, while oscillators are neutral. Recent Q2 2026 earnings missed estimates at $0.02 per share versus $0.06 expected, though revenue grew 10% year-over-year. The pending acquisition by Nuvei for $7.40 per share, announced June 15, 2026, anchors the price near deal terms, with legal inquiries ongoing regarding fairness.
Outlook is acquisition-driven with limited upside to the $7.40 offer, posing a 4.3% gain from current levels. Risks include deal completion uncertainty and earnings volatility, while opportunities lie in potential bid revisions. Analysts maintain a 60% buy rating with an $8.20 consensus target, suggesting confidence in long-term value beyond the takeover.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
